Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.34 |
| ▸ | FEN1 | P39748 | 3/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6746727 | 0.90 | PTGS2 (0.47) | PTGS2 | |
| SCHEMBL6744855 | 0.89 | PTGS2 (0.41) | PTGS2ALOX5APFEN1 | |
| SCHEMBL6743170 | 0.89 | PTGS2 (0.48) | PTGS2ACLY | |
| SCHEMBL6746862 | 0.89 | PTGS2 (0.31) | PTGS2 | |
| SCHEMBL6746733 | 0.88 | PTGS2 (0.34) | PTGS2ALOX5APFEN1ACLYNR1H2 | |
| SCHEMBL6744141 | 0.88 | PTGS2 (0.40) | PTGS2 | |
| SCHEMBL6745201 | 0.88 | ACLY (0.43) | PTGS2ALOX5APFEN1ACLYNR1H2 | |
| SCHEMBL6749677 | 0.87 | NR1H2 (0.36) | PTGS2ACLYNR1H2NR1H3 | |
| SCHEMBL6743648 | 0.87 | PTGS2 (0.40) | PTGS2ALOX5APFEN1NR1H2NR1H3 | |
| SCHEMBL6744624 | 0.86 | PTGS2 (0.38) | PTGS2NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699884-B2 | ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. | PHARMACIA CORPORATION | 2004-03-02 | — | — | US | claimed |
| US-6699884-B2 | ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. | PHARMACIA CORPORATION | 2004-03-02 | — | — | US | disclosed |